SCARB1 and prostate carcinoma: The mechanism of SR-BI-mediated transport of HDL cholesterol esters makes way for therapeutics to overcome faulty endo-lysosomal uptake routes, such as what was done by Lacko et al. whom engineered a paclitaxel-loaded reconstituted HDL vessel that was taken up by SR-BI expressing prostate cancer cell lines [106].